Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MF59-adjuvanted Influenza Vaccine in Elderly
NCT01162122Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Aug 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in influenza, sponsored by Novartis. Started Aug 2010; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01162122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01162122.